Hypertension - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2018’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypertension

The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects

The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Acceleron Pharma Inc

Ache Laboratorios Farmaceuticos SA

Actelion Pharmaceuticals Ltd

Aerogen Ltd

Anavex Life Sciences Corp

AnGes Inc

Arena Pharmaceuticals Inc

Ascendia ...

A1M Pharma AB

Acceleron Pharma Inc

Ache Laboratorios Farmaceuticos SA

Actelion Pharmaceuticals Ltd

Aerogen Ltd

Anavex Life Sciences Corp

AnGes Inc

Arena Pharmaceuticals Inc

Ascendia Pharmaceuticals LLC

Ascendis Pharma A/S

AVEO Pharmaceuticals Inc

Bayer AG

Bial - Portela & Ca SA

Bioblue Technologies Inc

Biogen Inc

Biolab Farmaceutica Ltda

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

CJ HealthCare Corp

Complexa Inc

Corion Biotech Srl

Cumberland Pharmaceuticals Inc

D. Western Therapeutics Institute Inc

Daewon Pharm Co Ltd

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Denovo Biopharma LLC

Eli Lilly and Co

Esperion Therapeutics Inc

FunPep Co Ltd

Galectin Therapeutics Inc

Gemphire Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

H. Lundbeck AS

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Idorsia Pharmaceutical Ltd

Ildong Pharmaceutical Co Ltd

Innopharmax Inc

Insmed Inc

Insys Therapeutics Inc

Ionis Pharmaceuticals Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

KBP BioSciences Co Ltd

Leading BioSciences Inc

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

LG Chem Ltd

LinXis BV

Liquidia Technologies Inc

MannKind Corp

Marina Biotech Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

N4 Pharma Plc

Nippon Shinyaku Co Ltd

Nissan Chemical Industries Ltd

Northern Therapeutics Inc

Novartis AG

Omeros Corp

Orion Corporation

Peloton Therapeutics Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Pulmokine Inc

Quantum Genomics SA

Reata Pharmaceuticals Inc

Relief Therapeutics Holding AG

Relypsa Inc

Renova Therapeutics Inc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

rEVO Biologics Inc

Roivant Sciences Ltd

Rottapharm Biotech Srl

Sanofi

Sarfez Pharmaceuticals Inc

Serodus ASA

Shanghai Pharmaceutical Co Ltd

SJT Molecular Research SL

SteadyMed Therapeutics Inc

Suda Pharmaceuticals Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Co Ltd

Target Medicals LLC

The Medicines Company

Theracos Inc

Theravance Biopharma Inc

Toray Industries Inc

United Therapeutics Corp

Vascular BioSciences

VG Life Sciences Inc

Vicore Pharma AB

Vivus Inc

XuanZhu Pharma Co Ltd

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Hypertension – Overview 8

Hypertension – Therapeutics Development 9

Hypertension – Therapeutics Assessment 34

Hypertension – ...

Table of Contents

Table of Contents 2

Introduction 7

Hypertension – Overview 8

Hypertension – Therapeutics Development 9

Hypertension – Therapeutics Assessment 34

Hypertension – Companies Involved in Therapeutics Development 52

Hypertension – Drug Profiles 103

Hypertension – Dormant Projects 539

Hypertension – Discontinued Products 556

Hypertension – Product Development Milestones 558

Appendix 567

List of Tables

List of Tables

Number of Products under Development for Hypertension, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Hypertension, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hypertension – Pipeline by A1M Pharma AB, H1 2018

Hypertension – Pipeline by Acceleron Pharma Inc, H1 2018

Hypertension – Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018

Hypertension – Pipeline by Actelion Pharmaceuticals Ltd, H1 2018

Hypertension – Pipeline by Aerogen Ltd, H1 2018

Hypertension – Pipeline by Anavex Life Sciences Corp, H1 2018

Hypertension – Pipeline by AnGes Inc, H1 2018

Hypertension – Pipeline by Arena Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by Ascendia Pharmaceuticals LLC, H1 2018

Hypertension – Pipeline by Ascendis Pharma A/S, H1 2018

Hypertension – Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by Bayer AG, H1 2018

Hypertension – Pipeline by Bial - Portela & Ca SA, H1 2018

Hypertension – Pipeline by Bioblue Technologies Inc, H1 2018

Hypertension – Pipeline by Biogen Inc, H1 2018

Hypertension – Pipeline by Biolab Farmaceutica Ltda, H1 2018

Hypertension – Pipeline by BioRestorative Therapies Inc, H1 2018

Hypertension – Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by Bristol-Myers Squibb Co, H1 2018

Hypertension – Pipeline by Camurus AB, H1 2018

Hypertension – Pipeline by Capricor Therapeutics Inc, H1 2018

Hypertension – Pipeline by Celsion Corp, H1 2018

Hypertension – Pipeline by Celtaxsys Inc, H1 2018

Hypertension – Pipeline by Chiesi Farmaceutici SpA, H1 2018

Hypertension – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Hypertension – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by CJ HealthCare Corp, H1 2018

Hypertension – Pipeline by Complexa Inc, H1 2018

Hypertension – Pipeline by Corion Biotech Srl, H1 2018

Hypertension – Pipeline by Cumberland Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by D. Western Therapeutics Institute Inc, H1 2018

Hypertension – Pipeline by Daewon Pharm Co Ltd, H1 2018

Hypertension – Pipeline by Daewoong Co Ltd, H1 2018

Hypertension – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Hypertension – Pipeline by Denovo Biopharma LLC, H1 2018

Hypertension – Pipeline by Eli Lilly and Co, H1 2018

Hypertension – Pipeline by Esperion Therapeutics Inc, H1 2018

Hypertension – Pipeline by FunPep Co Ltd, H1 2018

Hypertension – Pipeline by Galectin Therapeutics Inc, H1 2018

Hypertension – Pipeline by Gemphire Therapeutics Inc, H1 2018

Hypertension – Pipeline by Gilead Sciences Inc, H1 2018

Hypertension – Pipeline by GlaxoSmithKline Plc, H1 2018

Hypertension – Pipeline by H. Lundbeck AS, H1 2018

Hypertension – Pipeline by HanAll Biopharma Co Ltd, H1 2018

Hypertension – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Hypertension – Pipeline by Idorsia Pharmaceutical Ltd, H1 2018

Hypertension – Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by Innopharmax Inc, H1 2018

Hypertension – Pipeline by Insmed Inc, H1 2018

Hypertension – Pipeline by Insys Therapeutics Inc, H1 2018

Hypertension – Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by Japan Tobacco Inc, H1 2018

Hypertension – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by Johnson & Johnson, H1 2018

Hypertension – Pipeline by KBP BioSciences Co Ltd, H1 2018

Hypertension – Pipeline by Leading BioSciences Inc, H1 2018

Hypertension – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Hypertension – Pipeline by Les Laboratoires Servier SAS, H1 2018

Hypertension – Pipeline by LG Chem Ltd, H1 2018

Hypertension – Pipeline by LinXis BV, H1 2018

Hypertension – Pipeline by Liquidia Technologies Inc, H1 2018

Hypertension – Pipeline by MannKind Corp, H1 2018

Hypertension – Pipeline by Marina Biotech Inc, H1 2018

Hypertension – Pipeline by Merck & Co Inc, H1 2018

Hypertension – Pipeline by Mezzion Pharma Co Ltd, H1 2018

Hypertension – Pipeline by N4 Pharma Plc, H1 2018

Hypertension – Pipeline by Nippon Shinyaku Co Ltd, H1 2018

Hypertension – Pipeline by Nissan Chemical Industries Ltd, H1 2018

Hypertension – Pipeline by Northern Therapeutics Inc, H1 2018

Hypertension – Pipeline by Novartis AG, H1 2018

Hypertension – Pipeline by Omeros Corp, H1 2018

Hypertension – Pipeline by Orion Corporation, H1 2018

Hypertension – Pipeline by Peloton Therapeutics Inc, H1 2018

Hypertension – Pipeline by Pfizer Inc, H1 2018

Hypertension – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by Pulmokine Inc, H1 2018

Hypertension – Pipeline by Quantum Genomics SA, H1 2018

Hypertension – Pipeline by Reata Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by Relief Therapeutics Holding AG, H1 2018

Hypertension – Pipeline by Relypsa Inc, H1 2018

Hypertension – Pipeline by Renova Therapeutics Inc, H1 2018

Hypertension – Pipeline by Respira Therapeutics Inc, H1 2018

Hypertension – Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by rEVO Biologics Inc, H1 2018

Hypertension – Pipeline by Roivant Sciences Ltd, H1 2018

Hypertension – Pipeline by Rottapharm Biotech Srl, H1 2018

Hypertension – Pipeline by Sanofi, H1 2018

Hypertension – Pipeline by Sarfez Pharmaceuticals Inc, H1 2018

Hypertension – Pipeline by Serodus ASA, H1 2018

Hypertension – Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by SJT Molecular Research SL, H1 2018

Hypertension – Pipeline by SteadyMed Therapeutics Inc, H1 2018

Hypertension – Pipeline by Suda Pharmaceuticals Ltd, H1 2018

Hypertension – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Hypertension – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Hypertension – Pipeline by Target Medicals LLC, H1 2018

Hypertension – Pipeline by The Medicines Company, H1 2018

Hypertension – Pipeline by Theracos Inc, H1 2018

Hypertension – Pipeline by Theravance Biopharma Inc, H1 2018

Hypertension – Pipeline by Toray Industries Inc, H1 2018

Hypertension – Pipeline by United Therapeutics Corp, H1 2018

Hypertension – Pipeline by Vascular BioSciences, H1 2018

Hypertension – Pipeline by VG Life Sciences Inc, H1 2018

Hypertension – Pipeline by Vicore Pharma AB, H1 2018

Hypertension – Pipeline by Vivus Inc, H1 2018

Hypertension – Pipeline by XuanZhu Pharma Co Ltd, H1 2018

Hypertension – Pipeline by Yuhan Corp, H1 2018

Hypertension – Dormant Projects, H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..1), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..2), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..3), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..4), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..5), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..6), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..7), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..8), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..9), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..10), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..11), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..12), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..13), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..14), H1 2018

Hypertension – Dormant Projects, H1 2018 (Contd..15), H1 2018

Hypertension – Discontinued Products, H1 2018

Hypertension – Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development for Hypertension, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Hypertension, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports